These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37245700)

  • 21. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults.
    Miedema MD; Dardari ZA; Nasir K; Blankstein R; Knickelbine T; Oberembt S; Shaw L; Rumberger J; Michos ED; Rozanski A; Berman DS; Budoff MJ; Blaha MJ
    JAMA Netw Open; 2019 Jul; 2(7):e197440. PubMed ID: 31322693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis.
    Barbarawi M; Kheiri B; Zayed Y; Barbarawi O; Dhillon H; Swaid B; Yelangi A; Sundus S; Bachuwa G; Alkotob ML; Manson JE
    JAMA Cardiol; 2019 Aug; 4(8):765-776. PubMed ID: 31215980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omega 6 fatty acids for the primary prevention of cardiovascular disease.
    Al-Khudairy L; Hartley L; Clar C; Flowers N; Hooper L; Rees K
    Cochrane Database Syst Rev; 2015 Nov; (11):CD011094. PubMed ID: 26571451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
    Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety analysis of new medications in clinical trials: a simulation study to assess the differences between cause-specific and subdistribution frameworks in the presence of competing events.
    Genet A; Bogner K; Goertz R; Böhme S; Leverkus F
    BMC Med Res Methodol; 2023 Jul; 23(1):168. PubMed ID: 37442979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.
    Austin PC; Latouche A; Fine JP
    Stat Med; 2020 Jan; 39(2):103-113. PubMed ID: 31660633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-blockers for suspected or diagnosed acute myocardial infarction.
    Safi S; Sethi NJ; Nielsen EE; Feinberg J; Jakobsen JC; Gluud C
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012484. PubMed ID: 31845756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrates for primary prevention of cardiovascular disease events.
    Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009753. PubMed ID: 27849333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selenium supplementation for the primary prevention of cardiovascular disease.
    Rees K; Hartley L; Day C; Flowers N; Clarke A; Stranges S
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD009671. PubMed ID: 23440843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    Chang YH; Li WH; Chang Y; Peng CW; Cheng CH; Chang WP; Chuang CM
    BMC Cancer; 2016 Mar; 16():235. PubMed ID: 26988703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data.
    Diao G; Ibrahim JG
    Clin Trials; 2019 Aug; 16(4):363-374. PubMed ID: 31165631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applying competing risks regression models: an overview.
    Haller B; Schmidt G; Ulm K
    Lifetime Data Anal; 2013 Jan; 19(1):33-58. PubMed ID: 23010807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Misspecified regression model for the subdistribution hazard of a competing risk.
    Latouche A; Boisson V; Chevret S; Porcher R
    Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.